Last $2.72 USD
Change Today +0.05 / 1.87%
Volume 270.2K
RIGL On Other Exchanges
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/14 - $5.00
52 Week Low
12/18/13 - $2.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.

129 Employees
Last Reported Date: 03/4/14
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $695.1K
President and Chief Operating Officer
Total Annual Compensation: $551.7K
Co-Founder, Executive Vice President, Directo...
Total Annual Compensation: $559.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2013.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $25,456,000 against $22,885,000 a year ago. Net loss was $25,391,000 against $22,768,000 a year ago. Basic and diluted loss per share was $0.29 against $0.26 a year ago. For the six months, the company reported loss from operations of $47,841,000 against $48,595,000 a year ago. Net loss was $47,694,000 against $48,342,000 a year ago. Basic and diluted loss per share was $0.54 against $0.55 a year ago.

Rigel Pharmaceuticals, Inc. Initiates Phase 3 Studies of Fostamatinib in ITP

Rigel Pharmaceuticals, Inc. announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood. Fostamatinib in ITP Phase 3 Program Design: A total of 150 ITP patients will be randomized into two identical multi-center, double-blind, placebo-controlled clinical studies. The patients will have been diagnosed with persistent or chronic ITP, and have blood platelet counts consistently below 30,000 per microliter of blood. Two thirds of the subjects will receive fostamatinib orally at 100 mg bid (twice daily), the other third will receive placebo on the same schedule. Subjects are expected to remain on treatment for 24 weeks. At week 4 of treatment, subjects who meet certain platelet count and tolerability thresholds will have their dosage of fostamatinib (or corresponding placebo) increased to 150 mg bid. The primary efficacy endpoint of this program is a stable platelet response by week 24 with platelet counts at or above 50,000 per microliter of blood for at least 4 of the final 6 qualifying blood draws. Results are expected at year-end 2015. Immune Thrombocytopenic Purpura: Chronic ITP affects an estimated 60,000 - 125,000 people in the US. In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts. Current therapies for ITP include steroids, blood platelet production boosters (TPOs) and splenectomy. Fostamatinib is the only potential therapy that may address the autoimmune basis of the disease. Taken in tablet form, fostamatinib blocks the activation of SYK kinase inside immune cells. ITP causes the body to produce antibodies that attach to healthy platelets in the blood stream. Immune cells recognize these antibodies and affix to them, which activates the SYK enzyme inside the immune cell, and triggers the destruction of the antibody and the platelet. When SYK is inhibited by fostamatinib, it interrupts this immune cell function and allows the platelets to escape destruction.

Rigel Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-25-2014 09:30 AM

Rigel Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-25-2014 09:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $2.72 USD +0.05

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.29 USD -0.01
Array BioPharma Inc $4.01 USD +0.03
CrystalGenomics Inc 14,600 KRW +100.00
CTI BioPharma Corp $2.55 USD +0.02
Progenics Pharmaceuticals Inc $5.44 USD +0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.6x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at